Connor, Clark & Lunn Investment Management (CC&L)’s Atea Pharmaceuticals AVIR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$69.9K	Buy	+12,985	New	+$59.6K	﹤0.01%	1509
2025 Q2	–	Sell	-30,087	Closed	-$90K	–	1505
2025 Q1	$90K	Sell	30,087 -46,265	-61%	-$144K	﹤0.01%	1356
2024 Q4	$256K	Buy	76,352 +32,195	+73%	+$107K	﹤0.01%	1284
2024 Q3	$148K	Buy	+44,157	New	+$160K	﹤0.01%	1350
2024 Q2	–	Sell	-67,111	Closed	-$271K	–	1378
2024 Q1	$271K	Buy	67,111 +14,979	+29%	+$58.6K	﹤0.01%	1302
2023 Q4	$159K	Sell	52,132 -38,826	-43%	-$118K	﹤0.01%	1285
2023 Q3	$273K	Buy	90,958 +2,816	+3%	+$9.58K	﹤0.01%	1167
2023 Q2	$330K	Buy	+88,142	New	+$330K	﹤0.01%	1085

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AVIR Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in Atea Pharmaceuticals (AVIR) in Q1 2026: 12,985 shares worth $69.9K. The stake represents ﹤0.01% of the portfolio and ranks #1509 among its holdings. This is a return to the name: Connor, Clark & Lunn Investment Management (CC&L) previously reported a position in AVIR as recently as Q1 2025.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AVIR in Q2 2023 and has held it in 8 quarters since. The position peaked at $330K in Q2 2023. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 12,985 shares of Atea Pharmaceuticals worth $69.9K as of Q1 2026.
Atea Pharmaceuticals was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q1 2026.
Atea Pharmaceuticals made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1509 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Atea Pharmaceuticals in Q2 2023 and has held it in 8 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Atea Pharmaceuticals position peaked at $330K in Q2 2023.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.